Biotechnology & Medical Research

Vanda Pharmaceuticals Inc's Hetlioz receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind

Vanda Pharmaceuticals Inc:Announced that the European Commission (EC) approved HETLIOZ (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults in the European Union.

4:30pm EDT

Genticel receives positive DSMB opinion for unchanged continuation of procervix phase II trial

Genticel SA:Receives positive opinion from the DSMB for the continuation without change for the clinical trial protocol phase 2 for procervix (GTL001).

12:06pm EDT

XBiotech says clinical results supporting its true Human antibody therapy for type 2 diabetes mellitus

XBiotech Inc:Says publication of clinical results from an open label pilot study for its antibody therapy for treatment of Type 2 diabetes.MABp1 was well tolerated and no drug related adverse events occurred during the study.

7:35am EDT

Dyax Corp receives FDA breakthrough therapy designation for DX-2930

Dyax Corp:Says FDA granted Breakthrough Therapy designation for the investigation of DX-2930 for hereditary angioedema.In pre-specified proof-of-concept efficacy analysis, dx-2930 demonstrated statistically significant reductions in attack rate compared to placebo.Says designation is supported by...

7:15am EDT

Mergers & Acquisitions

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.